论文信息 - Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial - 字舞流文

Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial

R. Greil | H. Hackl | F. Huemer | T. Melchardt | G. Rinnerthaler | A. Egle | C. Hufnagl | C. Hauser-kronberger | T. Westphal | S. Gampenrieder | M. Steiner | T. Magnes | C. Monzo-Fuentes